Highlights newsletter 2
This newsletter presents you the following key sessions:
1. Video-interview with Timothy Hughes evaluating the treatment-free remission in patients with CML in chronic
phase according to reasons for switching from imatinib to nilotinib: a subgroup analysis from ENESTop
2. Association between c-MYC expression and progression free survival in multiple myeloma patients treated with
ixazomib-lenalidomide-dexamethasone
3. Phase III GALLIUM study shows superiority of obinutuzumab over rituximab in untreated patients with follicular
lymphoma
4. Blinatumomab delays the deterioration of health-related quality of life in patients with B-cell precursor acute
lymphoblastic leukemia
5. Peripherally inserted central catheters associated with a greater risk of thrombosis in children